daurismo
pfizer europe ma eeig - glasdegib maleate - leukæmi, myeloid, akut - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atopisk - andre dermatologiske præparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
lumykras
amgen europe bv - sotorasib - carcinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
bicalutamid "fair-med" 150 mg filmovertrukne tabletter
fair-med healthcare gmbh - bicalutamid - filmovertrukne tabletter - 150 mg
bicalutamid "fair-med" 50 mg filmovertrukne tabletter
fair-med healthcare gmbh - bicalutamid - filmovertrukne tabletter - 50 mg
bicalutamid "orion" 150 mg filmovertrukne tabletter
orion corporation - bicalutamid - filmovertrukne tabletter - 150 mg
bicalutamid "orion" 50 mg filmovertrukne tabletter
orion corporation - bicalutamid - filmovertrukne tabletter - 50 mg
bicalutamid "sandoz" 150 mg filmovertrukne tabletter
sandoz a/s - bicalutamid - filmovertrukne tabletter - 150 mg
bicalutamid "sandoz" 50 mg filmovertrukne tabletter
sandoz a/s - bicalutamid - filmovertrukne tabletter - 50 mg